Methods of treating alpha adrenergic mediated conditions

Details Methods of treating alpha adrenergic mediated conditions Methods of treating alpha adrenergic mediated conditions

2009-06-05

2011-11-22

Anderson, Rebecca (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

08063231

ABSTRACT:
Described herein are novel N-(2 and/or 3-substituted benzyl)-4,5-dihydro-1H-imidazol-2-amine derivatives processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals modulators of subtype α2Band/or α2Cadrenergic receptors.

REFERENCES:
patent: 4256755 (1981-03-01), Smith, Jr.
patent: 7072 (1969-06-01), None
patent: WO 03/099289 (2003-12-01), None
patent: WO 2006/127426 (2006-11-01), None
“Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557.
David J. Hart et al (J. Org. Chem. 48: 289-294 (1983).
Messier et al., 1995, Pharmacol. Toxicol. 76, pp. 308-311.
Kim and Chung 1992, Pain 150, pp. 355-363.
Dixon, W.J., Ann. Rev. Pharmacol. Toxicol. 20:441-462 (1980).

Affiliated with

Also associated with

Rating

Methods of treating alpha adrenergic mediated conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating alpha adrenergic mediated conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating alpha adrenergic mediated conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4298794